Who is sponsoring NCT05148702?

NCT05148702 is sponsored by Sarah Cockayne.

What drugs are being tested in NCT05148702?

Interventions in NCT05148702: Antibiotic - standard duration, Antibiotic - fixed-extended-duration.

What condition does NCT05148702 study?

NCT05148702 studies Complicated Intra-abdominal Infection.

Is NCT05148702 still recruiting?

NCT05148702 is currently recruiting now. Last updated 24 December 2024.

Last reviewed 2024-12-24 · How we verify

NCT05148702: EXTEND

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

EXTENDed Antibiotic Durations Compared to Standard Durations for Patients With Complicated Intra-abdominal Infection.

Recruiting now Phase 3 Last updated 24 December 2024

What this trial tests

Phase 3 trial testing Antibiotic - standard duration in Complicated Intra-abdominal Infection in 1,166 participants. Currently enrolling.

Timeline

10 October 2022

Primary endpoint
31 December 2025

31 December 2025

Quick facts

Lead sponsor	Sarah Cockayne
Phase	Phase 3
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	1,166
Start date	10 October 2022
Primary completion	31 December 2025
Estimated completion	31 December 2025
Sites	36 locations across United Kingdom

Drugs / interventions tested

Antibiotic - standard duration — full drug profile →
Antibiotic - fixed-extended-duration — full drug profile →

Conditions studied

Complicated Intra-abdominal Infection — all drugs for Complicated Intra-abdominal Infection →

Sponsor

Sarah Cockayne — full company profile →

Who can join

16 and older, any sex, with Complicated Intra-abdominal Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A multicentre, open label, two-arm, parallel group, pragmatic, randomised controlled trial with internal pilot. A total of 1166 consenting adult patients with cIAI will be recruited and randomised on a 1:1 basis between 28-days antibiotics and standard care antibiotics. Patients will be followed up for 180 days to determine cost effectiveness and the rate of treatment failure in each group.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Complicated Intra-abdominal Infection

Currently open trials in the same condition.

NCT05733104 — A Study to Learn About the Study Medicine Zavicefta After it is Released Into the Markets in Korea · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05148702 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sarah Cockayne
Last refreshed: 24 December 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05148702.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing